Calidi unveils fresh findings on CLD-401 at the 2025 SITC annual conference.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Calidi Biotherapeutics Presentation: Calidi Biotherapeutics showcased new data on its therapeutic candidate CLD-401 from the RedTail platform at the SITC Annual Meeting.
Key Findings: The data revealed that the RedTail platform can evade immune clearance after systemic administration and effectively target and replicate in tumor cells at metastatic sites.
Genetic Medicine Delivery: The platform demonstrated the ability to express genetic medicines at tumor sites in concentrations comparable to localized dosing while minimizing systemic exposure.
Expert Insight: Antonio Santidrian, PhD, emphasized the significance of these findings for advancing cancer treatment strategies.
Analyst Views on CLDI
About CLDI
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
